Overview

Valor Medical™ is a Delaware, C-Corp that has developed a proprietary and patent pending cyanoacrylate monomer which can be formulated to meet the needs of a wide range of clinical indications. The easy-to-handle monomer polymerizes on contact with blood or other body fluids into a firm, sponge-like material that effectively blocks liquid flow, allows tissue in-growth, and is broadly bactericidal.

Valor Medical is focusing its internal development on treatments for certain extremely serious cerebrovascular abnormalities, including aneurysms and arterial venous malformations (AVMs). In these indications, the monomer is formulated as a low-viscosity liquid and delivered via a microcatheter directly to the affected area. Upon release into the blood vessel, the product quickly polymerizes to form a safe and secure physical barrier that immediately stops dangerous blood flow. Other clinical applications of this platform technology that could be developed in partnership with major corporations include wound management (liquid bandage and trauma) and women's health (contraception and uterine fibroid embolization).

Valor Medical has completed cerebral aneurysm clinical trial outside the United States and received CE Mark approval in May 2011. The Company expects to begin European commercialization plans in mid-2012.

Industry analysts estimate that the cerebral aneurysm device market (coils and liquid embolics) will grow at a rate of ~20%, from $590 million in 2006 to $1.0 billion in 2014. Valor Medical's Neucrylate™ product line is projected to reach sales in the Neuro market of $32 million in 2015.